Merck's Answer to Pharma's Biggest Patent Cliff Costs $10.50 a Day
The first cholesterol pill in the PCSK9 class just reached US pharmacies at $315 a month — a tenth of what its injectable predecessors launched at. Inside the launch that has to fill the Keytruda hole, the revenue scenarios, and the three tickers on the wrong side of it.
Sometime this week, without much ceremony, a small white tablet began arriving on American pharmacy shelves. It is called Lipfendra, it is taken once a day, and it lowers LDL cholesterol — the kind that kills more Americans than anything else — by roughly 56% to 59% on top of a statin. The list price is $315 a month, about $10.50 a day.
That last number is the story. Because the drug class Lipfendra belongs to has been here before, with the same biology and nearly the same efficacy, and it failed — commercially — for a decade. What Merck launched this week is not just a new pill. It is a second attempt at one of the largest addressable markets in medicine, run by a company that needs the outcome more than any of its competitors do.
Merck's stock touched a 52-week high this week as the launch got underway. Whether that optimism is justified depends on some math we will get to below — because looming behind this launch is the loss of exclusivity on Keytruda, a roughly $30 billion franchise that has carried Merck for a decade and starts going away in 2028. Lipfendra is the first big test of whether Merck's answer to that cliff is real.
The class that failed
PCSK9 inhibitors should have been one of the great pharmaceutical franchises of the century. The science is elegant: PCSK9 is a protein that destroys the liver's LDL receptors — the machinery that clears bad cholesterol from the blood. Block PCSK9, and the liver keeps more of its receptors and pulls dramatically more LDL out of circulation. People born with natural PCSK9 mutations have very low cholesterol and strikingly low rates of heart disease. Rarely does drug discovery get a target this clean.
The first PCSK9 inhibitors — Amgen's Repatha and Sanofi/Regeneron's Praluent — arrived in 2015 as injectable antibodies, and Wall Street penciled in multibillion-dollar blockbusters. Then came the launch price: around $14,000 a year. Insurers responded with some of the most aggressive gatekeeping ever deployed against a new drug class — prior authorizations, step therapy, denial rates that became the subject of academic studies. By 2018, both manufacturers had capitulated, cutting list prices by roughly 60% to around $5,850 a year. Even then, the class never came close to early forecasts. A decade in, Repatha — the category leader — generates on the order of $2 billion a year globally. Novartis bought its way in with Leqvio, a twice-yearly injection, and has still found the going slow.
The lesson the industry took away: the barrier was never the biology. It was the needle, the price, and the paperwork.
What Merck actually built
Lipfendra (enlicitide) is the first oral PCSK9 inhibitor — a macrocyclic peptide, a ring-shaped molecule large enough to block a protein-protein interaction that small molecules cannot touch, but engineered to survive the gut, which peptides normally do not. Merck formulates it with a permeation enhancer that briefly loosens the junctions between intestinal cells to let the drug through. It is a genuine piece of chemistry: for years, "oral PCSK9" was something of a white whale in cardiometabolic drug development.
The FDA approved it on July 15 on the strength of two Phase 3 trials from the CORALreef program, covering about 3,200 adults already on maximally tolerated statins. In CORALreef Lipids, LDL cholesterol fell 56% versus placebo at week 24. In CORALreef HeFH — patients with heterozygous familial hypercholesterolemia, an inherited condition affecting roughly 1 in 250 people — the reduction was 59%. Side effects overall tracked placebo. That is injectable-class efficacy in a once-daily tablet.
There is one catch worth knowing about, because it will matter commercially: the pill must be taken fasting — food interferes with the absorption trick that gets the peptide into the bloodstream. A daily tablet with a fasting window is not quite the frictionless experience the "statin-like simplicity" headlines suggest. Adherence data over the next year will show how much that matters.
And then there is the price. At $315 a month — roughly $3,800 a year — Merck has listed the pill at a fraction of what the injectables launched at a decade ago, and well below where their list prices sit even after the great 2018 climbdown. That is not generosity. It is strategy, shaped by a decade of scar tissue and a political environment in which drugmakers, Merck included, have been signing public pricing agreements with the White House. Merck is choosing volume over margin from day one.
Which raises the question this launch actually turns on: how much volume does Merck need for this pill to fill the hole Keytruda is about to leave — and who ends up on the wrong side of the trade if it works?
The rest of this briefing is for paid members: the Keytruda cliff arithmetic and what Merck has promised investors to cover it, three patient-capture scenarios with the revenue math behind each, the three listed names most exposed if the launch works, and the two catalysts — one in January 2027, one at the end of the decade — that will decide the stock's next leg.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish — the analysis private intel clients pay four figures for, at a fraction of that.